UroGen Pharma Ltd. Quarterly Depreciation, Depletion and Amortization in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary
UroGen Pharma Ltd. quarterly/annual Depreciation, Depletion and Amortization history and growth rate from Q1 2018 to Q3 2024.
  • UroGen Pharma Ltd. Depreciation, Depletion and Amortization for the quarter ending September 30, 2024 was $100K, a 50% decline year-over-year.
  • UroGen Pharma Ltd. Depreciation, Depletion and Amortization for the twelve months ending September 30, 2024 was $508K, a 45.1% decline year-over-year.
  • UroGen Pharma Ltd. annual Depreciation, Depletion and Amortization for 2023 was $802K, a 13.2% decline from 2022.
  • UroGen Pharma Ltd. annual Depreciation, Depletion and Amortization for 2022 was $924K, a 11.2% increase from 2021.
  • UroGen Pharma Ltd. annual Depreciation, Depletion and Amortization for 2021 was $831K, a 99.8% increase from 2020.
Depreciation, Depletion and Amortization, Trailing 12 Months (USD)
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $508K $100K -$100K -50% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $608K $100K -$100K -50% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $708K $123K -$94K -43.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $802K $185K -$124K -40.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $926K $200K $0 0% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $926K $200K $0 0% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $926K $217K +$2K +0.93% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $924K $309K +$69K +28.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $855K $200K $0 0% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $855K $200K $0 0% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $855K $215K +$24K +12.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $831K $240K +$124K +107% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 $707K $200K +$100K +100% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $607K $200K +$100K +100% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $507K $191K +$91K +91% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $416K $116K +$116K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-21
Q3 2020 $300K $100K $0 0% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $300K $100K $0 0% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $300K $100K $0 0% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $300K $0 -$52.5K -100% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-18
Q3 2019 $352K $100K $0 0% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $352K $100K +$52.5K +110% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $300K $100K -$100K -50% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $400K $52.5K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 $100K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $47.5K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $200K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.